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Abstract 
Paclitaxel is an antineoplastic drug used against a variety of tumors, but its low aqueous 
solubility and active removal caused by P-glycoprotein in the intestinal cells hinder its oral 
administration. In our study, new type of stabilized Pluronic micelles were developed and 
evaluated as carriers for paclitaxel delivery via oral or intravenous route. The pre-stabilized 
micelles were loaded with paclitaxel by simple solvent/evaporation technique achieving high 
encapsulation efficiency of 70 %. Gastrointestinal transit of the developed micelles was 
evaluated by oral administration of rhodamine-labeled micelles in rats. Our results showed 
prolonged gastrointestinal residence of the marker encapsulated into micelles, compared to a 
solution containing free marker. Further, the oral administration of micelles in mice showed 
high area under curve of micellar paclitaxel (similar to the area of i.v. Taxol), longer mean 
residence time (9-times longer than i.v. Taxol) and high distribution volume (2-fold higher 
than i.v. Taxol) indicating an efficient oral absorption of paclitaxel delivered by micelles. 
Intravenous administration of micelles also showed a significant improvement of 
pharmacokinetic parameters of micellar paclitaxel vs. Taxol, in particular higher area under 
curve (1.2-fold), 5-times longer mean residence time and lower clearance, indicating longer 
systemic circulation of the micelles.  
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Graphical abstract 
Schematic presentation describing the improved pharmacokinetic parameters achieved by 
administration of paclitaxel-loaded stabilized Pluronic micelles (PTX-PM). For comparison, 
the same parameters calculated after administration of paclitaxel in the form of commercial 
solution (Taxol). 
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1. Introduction 
Polymeric micelles present a great potential as drug delivery systems for compounds that 
are hydrophobic and exhibit poor bioavailability. The unique core-shell structure of micelles 
enables incorporation of poorly soluble drugs into the inner hydrophobic core thus improving 
their stability and bioavailability. The hydrophilic shell plays an important role for the in vivo 
behavior of the micelles, in particular their steric stabilization and ability to interact with the 
cells. According to some references polymeric micelles could facilitate drug transport by fluid 
phase endocytosis as well as to provide receptor mediated transport by functionalization of 
the shell (Torchilin, 2004; Mathot et al., 2007).  
The micelles of poly(ethylene oxide)-b-poly-(propylene oxide)-b-poly(ethylene oxide) 
(PEO–PPO–PEO)  amphiphilic triblock copolymers are evaluated as drug and gene delivery 
systems, as well as in diagnostic imaging as carriers for various contrasting agents (Kabanov 
et al., 2002). PEO–PPO–PEO micelles can be prepared from commercially available 
copolymers (Pluronics) and combine several attractive properties, including resistance of the 
PEO shell to protein adsorption, ability of the temperature responsive PPO core to solubilize 
water-insoluble compounds and availability of hydroxyl groups to which receptor-specific 
ligands can be attached (Alexandridis and Hatton, 1995). Since the formation of PEO–PPO–
PEO micelles is a dynamic phenomenon, one possible drawback may be associated with 
micellar disaggregation upon dilution at physiological conditions. Rapoport and co-workers 
proposed different strategies for stabilization of PEO–PPO–PEO micelles, in particular 
radical cross-linking of micelle core using benzoyl peroxide as radical initiator, introduction 
of vegetable oil aiming to increase hydrophobic interactions within the core, or formation of  
hydrogel inside the micelle core (Plurogel®) (Rapoport, 1999). More recently, an efficient 
method for the stabilization of PEO-PPO-PEO micelles by UV-induced formation of an 
interpenetrating network of poly(pentaerythritol tetraacrylate), in which the polyether chains 
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were physically entrapped, has been reported (Petrov et al., 2006). The stabilized polymeric 
micelles (SPM) resisted changes in concentration and solvent and maintained their structure 
and size even when ultrasound irradiated at 20 kHz. 
Paclitaxel (PTX) is an antineoplastic drug successfully used against a variety of tumors 
including ovarian, breast and non-small cell lung tumors (Gregory and DeLisa, 1993; Chen et 
al., 2003).  In clinics, paclitaxel is intravenously administered as infusion (i.e. Taxol®). Due 
to its limited aqueous solubility (0.3 μg/ml), the commercial injectable formulations use a 
mixture of Cremophor EL and ethanol (1:1 v/v) (Singla et al., 2002). Apart from other 
problems, the presence of Cremophor EL results in hypersensitivity reactions, nephrotoxicity, 
and neurotoxicity (Onetto et al., 1993). In addition, this pharmaceutical excipient can also 
modify the pharmacokinetics of PTX (Sparreboom et al., 1999). To overcome these problems, 
several alternative pharmaceutical carriers have been developed for PTX delivery including 
liposomes (Wang et al., 2010; Zhao et al., 2011), polymeric micelles (Hamaguchi et al., 2005; 
Forrest at el., 2008) and nanoparticles (Koziara et al., 2006; Win and Feng, 2006). In the last 
years, different paclitaxel formulations have been clinically studied such as Opaxio® 
(formerly Xyotax®) and Abraxane®. The former is a polymer conjugate between paclitaxel 
and poly(glutamate) (Boddy et al., 2005) whereas the latter, which was recently 
commercialised, is based on the incorporation of paclitaxel in human serum albumin 
nanoparticles (Roy et al., 2009). 
On the other hand, a number of different attempts have been performed to develop oral 
formulations of paclitaxel. Nevertheless, apart from the low aqueous solubility, oral treatment 
with paclitaxel is hampered by the fact that the drug is substrate of the P-glycoprotein and 
cytocrome P-450 (Letchford et al., 2009). As a result the oral bioavailability of paclitaxel is 
extremely low (Malingre et al., 2001). In the last years, different approaches have been 
proposed to solve this problem including the co-administration of pharmaceutical excipients 
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with capability to disturb the effect of intestinal P-gp and/or cytocrome P450. In this context, 
the combination between cyclodextrins and poly(anhydride) nanoparticles yielded oral 
bioavailability up to 85 % in rat. In this approach, the cyclodextrin permits to promote the 
encapsulation of the lipophilic drug into the nanoparticles and to inhibit the activity of the P-
gp, whereas the function of poly(anhydride) nanoparticles is to develop bioadhesive 
interactions within the gastrointestinal mucosa and control the release of their content 
(Agüeros et al., 2010). 
The aim of this work was to prepare, characterize and evaluate the pharmacokinetics of 
paclitaxel incorporated in stabilized Pluronic micelles. The stabilization of micelles by cross-
linking of their core was performed aiming to prevent disaggregation of micelles upon 
dilution in physiological fluids. On the other hand, drug encapsulation in micelles can 
diminish drug extravasation to normal tissues and provide a passive drug targeting to tumors 
via the enhanced permeability and retention effect (EPR) (Maeda et al., 2000). This increased 
permeability is favorised by the prolonged circulation of micelles and lack of renal clearance 
(Han et al., 2006; Batrakova et al., 2008). On the other hand, Pluronic copolymers (as other 
pharmaceutical excipients) may inhibit the activity of drug efflux transporters such as P-gp, 
MRPs and BCRP (Kabanov et al., 2002; Thomas et al., 2003; Huang et al., 2008). Thus, the 
combination of these properties with the fact that the shell of polymeric micelles could 
establish interactions with the cells may be an adequate strategy to (i) increase the oral 
bioavailability and/or (ii) promote the efficacy of the loaded drug.  
 
2. Materials and methods 
2.1. Materials 
PEO43PPO15PEO43 (Pluronic F-38; MW 4700 gmol-1) were kindly donated by BASF 
Pentaerythritol tetraacrylate (PETA) and rhodamine B were purchased from Aldrich. 
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Paclitaxel (USP 26 grade >99.5%) was supplied by 21CEC (London, United Kingdom). 
Docetaxel (Taxotere) was provided by Sanofi-Aventis (Paris, France). Taxol® was 
purchased from Bristol-Myers Squibb (New York, USA). All other solvents and reagents 
were of analytical grade. 
 
2.2. Preparation of stabilized Pluronic micelles (PM) 
PEO43PPO15PEO43 (5 g) was dissolved in 250 ml double distilled water in a glass vessel 
under stirring. Acetone solution of PETA (0.05g/ ml) was added and the temperature of the 
solution was increased to 60 oC. Argon was bubbled through the solution for 45 min, followed 
by irradiation with a full spectrum UV light (TQ 150 Original Hanau high-pressure 150 W 
mercury lamp provided with a quartz tube and a cooling quartz jacket) for 45 min. The 
stabilized polymeric micelles were purified by dialysis against water using a cellulose 
membrane (Sigma, cutoff 12,000 gmol-1) for 14 days. Finally, the micelles dispersion was 
frozen and subsequently lyophilized. 
 
2.3. Loading of pre-stabilized Pluronic micelles with rhodamine (R-PM) 
The pre-stabilized micelles were fluorescently labelled with rhodamine B by solvent 
evaporation technique. For this purpose, 10 ml ethanol solution of rhodamine (concentration 
0.1 mg/ml, 0.15 mg/ml or 0.3 mg/ml) was added to 10 ml of aqueous dispersion of the 
stabilized micelles (3 mg/ml) and the compounds were incubated for 24h. The ethanol was 
evaporated under reduced pressure (Buchi-144, Switzerland) and dialysis of the aqueous 
dispersion towards distilled water (Sigma, cutoff 12,000 g mol-1) was performed in order to 
eliminate the free rhodamine. Finally, the purified aqueous dispersion containing rhodamine 
loaded micelles was lyophilized (Genesis 12EL, Virtis, USA) using sucrose as cryoprotector 
(5 % w/v). 
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2.4. Loading of pre-stabilized Pluronic micelles with paclitaxel (PTX-PM) 
Ten ml of ethanol solution of paclitaxel (concentration 0.1 mg/ml, 0.15 mg/ml or 0.3 
mg/ml) was added to 10 ml of aqueous dispersion of the pre-stabilized micelles (3 mg/ml) and 
the compounds were incubated for 24h. The ethanol was evaporated under reduced pressure 
(Buchi-144, Switzerland) and the resulted micelle dispersion was filtered (0.22 μm). The filter 
was rinsed with ethanol and these fractions were determined for non-encapsulated paclitaxel. 
The aqueous dispersion containing paclitaxel loaded micelles was lyophilized (Genesis 12EL, 
Virtis, USA) using sucrose as cryoprotector (5 % w/v). 
 
2.5. Characterisation of the micelles 
Size and zeta-potential were determined by photon correlation spectroscopy and 
electrophoretic laser doppler anemometry using a Zetamaster analyzer (Malvern Instruments, 
UK). Samples were dispersed in either distilled water or saline (0.154 M and 0.308 M NaCl 
solution) and measured at 25oC with a scattering angle of 90o. 
 
2.6. Determination of drug loading 
The amount of rhodamine incorporated into the R-PM was determined by 
spectrofluorimetry at wavelength λex =540nm and λem =580nm (GENios, Austria). The marker 
loading was calculated as a difference between its initial concentration and the concentration 
found in the aqueous fractions collected after the dialysis procedure. For the calculations 
standard curve of rhodamine B in distilled water was prepared in the concentration range of 
0.2-4.0 μg/ml (r>0.9978). 
The amount of paclitaxel incorporated into the PTX-PM was calculated as a difference 
between its initial concentration and the concentration found in the ethanol rinsing fractions. 
Paclitaxel was determined by HPLC method, in particular the chromatographic system was an 
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Agillent 1100 series (Waldbornn, Germany), coupled with a UV diode array detection system 
(25). Data were analyzed using the Chemstation G2171 program (B.01.03). The separation of 
PTX was carried out at 30ºC on a reversed-phase 150 x 3 mm C18 Phenomenex Gemini 
column (particle size 5 m). The mobile phase, pumped at 0.5 ml/min, was 50:50 acetonitrile 
- phosphate buffer (0.02 M, pH=2.0) and effluent was monitored with UV detection at 228 
nm. For the calculations standard curve of paclitaxel was prepared in the concentration range 
of 1.25-80.0 μg/ml (r>0.9991). The limit of quantification was calculated as 40 ng/ml with a 
relative standard deviation of 5.2 %. 
The equations used for calculation of theoretical drug loading, actual drug loading and 
encapsulation efficiency are given bellow: 
 
          
              
 
2.7. Distribution of R-PM within the gut 
The study was performed in compliance with the regulations of the responsible committee 
of the University of Navarra in line with the European legislation on animal experiments 
(86/609/EU). Rhodamine B labelled micelles were administered in the form of aqueous 
suspensions (10 mg/ml) to fasted Wistar rats orally. The animals were sacrificed by cervical 
dislocation at 1, 3 and 8 h post administration. The abdominal cavity was opened and GIT 
was removed and divided into three regions: stomach, small intestine and caecum. Each 
segment was opened lengthwise along the mesentery and rinsed with phosphate saline buffer 
Theoretical drug loading (%)  = 
Weights of drug and stabilized micelles 
Weight of drug initially added 
X 100 
Actual drug loading (%)  = 
Weight of drug loaded micelles 
Weight of drug incorporated into micelles 
X 100 
Encapsulation efficiency (%)  = 
Theoretical drug loading 
Actual drug loading 
X 100 
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(pH 7.4) in order to eliminate the lumen contents. Further, each segment was cut into portions 
of 2 cm length and digested in 1 ml of 3N NaOH for 24 h (Arbos et al., 2002). Rhodamine 
was extracted with 2 ml methanol, vortexed for 1 min and centrifuged at 4000 rpm for 10 
min. Aliquots (1 ml) of the supernatants were assayed for rhodamine by spectrofluorimetry 
(GENios, Austria) to estimate the fraction of the micelles within gastrointestinal mucosa. 
Calculations were made using standard curves of rhodamine prepared by addition of 
rhodamine solutions in 3N NaOH (0.5-10 g/ml) to tissue segments following the same 
treatment steps. 
Control rhodamine solution (119 μg/ml) was administered to rats and the presence of 
rhodamine within gastrointestinal mucosa was determined following the same procedures as 
above.   
 
2.8. Pharmacokinetic study in mice  
Animal experiments were performed in compliance with regulations of the responsible 
Ethical Committee of the University of Navarra (protocol number 076-06) in strict accordance 
with the European legislation in animal experiments. Female C57BL/6J mice (average weight 
20 g) (Harlan, Spain) were housed under normal conditions with free access to food and 
water. The animals were placed in metabolic cages and fasted overnight to prevent 
corpophagia but allowing free access to water.  
For the pharmacokinetic study, the mice were divided at random into 4 groups (n=5). The 
first two groups received orally a single dose (10 mg paclitaxel/kg) of either (i) commercial 
Taxol or (ii) paclitaxel-loaded micelles (PTX-PM). Besides, Taxol and PTX-PM were also 
intravenously administered to the other two groups of mice at the same dose (10 mg/kg). 
All the formulations were administered dispersed or dissolved in 1 ml of water (oral) or 
saline (intravenous). Blood samples of 200 l were collected at different times in tubes 
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containing EDTA (Microvette® EDTA tripotassium salt; Sarstedt, Numbrecht, Germany). 
The volemia was recovered via intraperitoneal injection of an equal volume of normal saline 
solution preheated at body temperature. Blood samples were centrifuged for 10 min at 10,000 
rpm and the supernatant plasma fractions were stored at -80ºC until HPLC analysis. 
 
2.9. HPLC quantification of paclitaxel in plasma samples 
The amount of paclitaxel was determined in plasma by HPLC as described above. 
Calibration curves were used for the conversion of the PTX/DCX chromatographic area to the 
concentration. Calibrator and quality control samples were prepared by adding appropriate 
volumes of standard PTX ethanol solution to drug free plasma. Calibration curves were 
designed over the range of 40–3200 ng/ml (r2>0,999). An aliquot (100 l) of plasma sample 
was mixed with 25 l of internal standard solution (docetaxel, 4 g/ml in methanol, 
previously evaporated). After vortex mixing, liquid-liquid extraction was accomplished by 
adding 4 ml of tert-buthylmethylether following vortex gentle agitation (1 min). The mixture 
was centrifuged for 10 min at 5000 rpm, the organic layer was transferred to a clean vial and 
evaporated until dry (Savant, Barcelona, Spain). Finally, the residue was dissolved in 125 l 
of reconstitution solution (acetonitrile/0,01M phosphate buffer, 50/50 v/v, pH=2.0) and 
transferred to auto-sampler vials, capped and placed in the HPLC auto sampler. A 100 l 
aliquot of each sample was injected onto the HPLC column. 
Under these experimental conditions the run time was 14 min. The limit of quantification 
was calculated as 80 ng/ml with a relative standard deviation of 5.2 %. Accuracy values 
during the same day (intra-day assay) at low, medium and high concentrations of PTX was 
always within the acceptable limits (-1.81 and 3.49 %) at all concentrations tested. 
 
2.9. Pharmacokinetic data analysis 
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The pharmacokinetic analysis of concentration-time data, obtained after the administration 
of the different PTX formulations, were analyzed using a noncompartimental model using 
Phoenix WinNonlin 6.0 software (Pharsight Corporation, Mountain View, EEUU). The 
pharmacokinetic parameters estimated were: the peak of maximun concentration (Cmax), time 
to peak concentration (Tmax), the half-life of the terminal phase (t1/2), the area under the 
concentration-time curve from time 0 to 8 or 24 hours (AUC0-8, AUC0-24), the mean residence 
time (MRT) and the total body clearance (Cl). The mean residence time (MRT) was 
calculated as the AUMC (area under the concentration-time curve at the first moment) divided 
by AUC. The absolute availability (F) was calculated according to:  
F= AUCoral / AUCi.v.              
where AUCoral and AUCi.v. were the area under the concentration-time curve after the oral and 
i.v. administration, respectively.  
 
2.10. Statistical analysis 
The results were expressed as mean values  SD. The Mann-Withney U-test was used to 
investigate statistical differences. In all cases, p < 0.05 was considered to be significant. All 
calculations were performed using SPSS® statistical software program (SPSS® 14, Microsoft, 
USA).   
 
3. Results  
3.1. Characterization of the micelles 
The main physico-chemical properties of the micelles are presented in Table 1. The 
resulted stabilized micelles have an average diameter less than 200 nm, narrow distribution 
and negative zeta-potential values. As shown, drug-loaded micelles did not differ in size 
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compared to the non-loaded micelles. The latter is due to the fact that the dense poly-PETA 
network locks the micellar structure and does not allow any re-arrangement and expansion.  
Physical stability of the stabilized micelles was evaluated by observation of their size and 
polydispersity with time. The size was measured in aqueous media with increasing salt 
concentration aiming to investigate the influence of the ionic strength. The ratio between the 
size observed after 24 hours in different media (aqueous dispersion, 0.154 M and 0.308 M 
NaCl solution) to initial size measured in distilled water was calculated (Figure 1). Since the 
size ratios were in a narrow range, the micelles were considered stable.  
In order to evaluate the influence of the initial drug/stabilized micelles ratio on drug 
loading degree, different concentrations of rhodamine/ paclitaxel with respect to the micelle 
concentration were varied. The results demonstrated that the increase of the initial 
concentration from 1 to 1.5mg increased loading degree for both molecules (Figure 2). 
However, further increase of initial paclitaxel concentration decreased encapsulation 
efficiency suggesting that the optimal ratio between initial paclitaxel and stabilized micelles 
was 1:20.  
 
3.2. Gastrointestinal transit of the stabilized micelles 
The study was performed using the stabilized micelles loaded with rhodamine (R-PM) as 
described above (an initial ratio 1:20). The study included oral administration of micelles and 
evaluation of the localization of rhodamine in the gastrointestinal mucosa. In parallel, control 
solution of rhodamine with a concentration similar to the rhodamine concentration into the 
micelles was administered. The results showed that the total amount of rhodamine within the 
gastrointestinal mucosa decreased with time (Figure 3). In fact, one hour post administration 
about 40 % of the given dose was found in the mucosa (mainly in the stomach) whereas, 2 
hours later, only 21 % of the rhodamine dose remained within the mucosa. The rhodamine 
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dose remained 8 h post-administration (18 %) was similar to that found 3 h post-
administration, which clearly demonstrated the prolonged transit of micellar rhodamine. In 
any case, these percentages were significantly higher (p<0.05) than those observed for the 
control solution of rhodamine (Figure 4).   
 
3.3. Pharmacokinetic study of paclitaxel when loaded in stabilized Pluronic micelles 
For the pharmacokinetic study, Taxol and PTX-PM were intravenously or orally 
administered to mice. Figure 5 illustrates plasma profiles of PTX after i.v. administration of 
PTX-loaded micelles or Taxol to mice. As shown, plasma concentrations of both 
formulations (micelles and commercial) were similar during the first hour post-
administration. Then, plasma curve of PTX-PM was characterised by a plateau in the 
concentration during at least 2 hours followed by a low decrease with time. On the contrary, 
for Taxol®, the plasma curve was characterised by a rapid decline in the paclitaxel plasma 
levels during the first 2 h after administration followed by a slow fall of drug concentrations 
till the end of the experiment (8 hours). Under these circumstances, the micelles provided 
higher AUC (1.2-fold) compared to Taxol (Table 2). Further, when commercial Taxol was 
administered to mice by the oral route, no PTX plasma levels were found (Figure 6). On the 
contrary, when PTX was included into micelles, these formulations displayed drug levels in 
plasma for at least 8 h. The plasma curve was characterised by a high Cmax 30 min post-
administration, only 3-times lower than that obtained with the same formulation i.v. 
administered (Table 2), followed by a slow and almost constant decline during the following 
8 hours. The oral bioavailability of paclitaxel when loaded into the stabilized Pluronic 
micelles was calculated to be about 0.9. 
 
4. Discussion 
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Dynamic core-shell micelles of PEO43PPO15PEO43 copolymer were stabilized by UV –
induced crosslinking of tetrafunctional acrylate, PETA, within the micelles according to 
procedure described elsewhere (Petrov et al., 2008). Pentaerythritol tetraacrylate was applied 
as cross-linking agent because of its ability to form an interpenetrating network in which the 
polyether chains are physically entrapped. Previous studies have shown that the micelles 
obtained with large amount of PETA (10–50 mass% with respect to PPO fraction) are 
extremely stable and do not disaggregate upon dilution in water and organic solvents and 
maintain their integrity even when irradiated with ultrasound (Petrov et al., 2006). In the case 
of aggregates stabilized with smaller amount of PETA (3 mass %), copolymer molecules can 
dissociate from the polymer network resulting in aggregates dissociation (Li et al., 2007). 
Thus, one may play with the long-term stability of the micelles by tuning the density of poly-
PETA network. Taking into account the above considerations, the cross-linking agent was 
used in a concentration of 30 % with respect to PPO fraction. This network does not decrease 
noticeably the loading capacity of PPO core and, on the other hand, does not influence the 
flexibility of extended hydrophilic PEO-chains of resulted stabilized micelles. The latter is 
very important taking into account that the mobility of hydrophilic chains on the periphery of 
drug carriers determines both the stability and the in vivo distribution of the particles. In this 
view, our observations showed that the size and polydispersity of the stabilized Pluronic 
micelles did not change even in the presence of electrolyte. This fact suggested that the PEO 
chains are extended and prevent any agglomeration of the micelles in the presence of 
electrolytes.   
Two methods have been reported for loading of polymeric micelles with drug molecules, 
in particular physical and chemical loading (Jones and Leroux, 1999). The second method 
includes formation of chemical bonds between drug molecule and polymeric carrier, usually 
during the process of micelles formation. In the present study the first method was applied. 
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The pre-stabilized micelles were loaded with fluorescent marker rhodamine B or with 
paclitaxel by solvent evaporation technique. Comparing both molecules, higher loading and 
encapsulation efficiency was achieved with paclitaxel. The latter fact was explained with the 
more hydrophobic nature of paclitaxel (logP of 3.5) than rhodamine (logP of 1.95).   
Gastrointestinal transit of the stabilized micelles was evaluated by oral administration to 
rats. The most important finding was that the transit of the rhodamine-loaded micelles was 
prolonged compared to the control solution of free rhodamine. Thus, 8 hours after 
administration only 6 % of rhodamine applied in the form of solution was spread on the whole 
GIT versus 18 % for stabilized micelles (Figure 4). Another interesting point was that the 
micelles were concentrated in the small intestine of animals after oral administration (I3 and 
I4 portions in Figure 3). All of these results appear to be in line with previous studies about 
the interaction of micelles with the intestinal mucosa (Gaucher et al., 2010). In fact, the size 
and hydrophilicity of the shell may limit their interaction with the gut contents and would 
favour the diffusion of these carriers through the mucus layer. Similar phenomenon has been 
previously reported for pegylated poly(anhydride) nanoparticles (Yoncheva et al., 2007). The 
authors postulated that the “brush” layer of PEG-chains reduced an interaction between 
nanoparticles and mucin, which corresponded to better adhesion and facilitated their proximal 
contact with enterocytes. In the present study, the extended flexible PEO-chains in the micelle 
shell probably function in a similar way.  
Intravenous administration of Taxol and PTX-PM into mice showed a significant 
improvement of pharmacokinetic parameters after administration of micellar paclitaxel (Table 
2). More important, the higher MRT (about 5-times) and lower Cl values (about 2-fold) 
indicated that PTX-PM formulation increased the time of systemic circulation. This fact could 
be explained with the protective “stealth” properties of micelle PEO-shell that hinders their 
recognition and uptake by the cells of RES. These results are in agreement with previous data 
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published by Kabanov and collaborators (Kabanov et al., 2002). This manuscript studied the 
pharmacokinetics and biodistribution of Pluronics after single i.v. administration and reported 
that these block copolymers remained in circulation a substantial period of time.  The results 
obtained after oral administration of our stabilized micelles were even more interesting. The 
AUC calculated after oral administration of micelles was similar to that calculated for the i.v. 
administration of Taxol (Table 2). On the other hand, the mean residence time of paclitaxel 
after oral administration of PTX-PM was almost two-times longer than that achieved after i.v. 
administration of micelles and 9-times longer than Taxol. These data together with the low 
clearance and high distribution volume (2-fold higher than i.v. Taxol) indicated efficient oral 
absorption of PTX. In our opinion, the efficient oral absorption of PTX is associated with the 
properties of the stabilized micelles. Based on the results from the biodistribution studies with 
rhodamine loaded micelles (R-PM) it could be considered that the flexible PEO-chains in 
micelles shell enable micelle penetration through the mucus layer, facilitating their transport 
to the absorptive surface of the enterocytes. On the other hand, it has been described that 
Pluronics and other non-ionic surfactants inhibit the activity of intestinal Pgp (Batrakova et 
al., 1998a; 1998b). This fact has been explained by a combination of decreased ATPase 
activity and ATP depletion due to increased membrane fluidity (Batrakova et al., 2004; 
Bansal et al., 2009). Nonetheless, studies performed on various cell models have shown that 
polymeric micelles could be internalized, with fluid-phase pinocytosis appearing as a major 
route (Allen et al., 1999; Luo et al., 2002). More recently, Mathot et al. have found that 
micelles obtained from monomethylether poly(ethyleneglycol)(750)-poly(caprolactone-co-
trimethylene carbonate) can cross lipid bilayers via passive diffusion and demonstrate an oral 
bioavailability of 40 % in rats (Mathot et al., 2007). Taking into account these reports, the 
results in the present study may be explained by an increased absorption of paclitaxel when 
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loaded into the newly developed stabilized micelles, an absorption or translocation of micelles 
through the gastrointestinal mucosa or a combination of both phenomena. 
In summary, the present study demonstrated the development of new, in particular 
stabilized micelles, as paclitaxel delivery system. The extended PEO-chains in the micelle 
shell probably enabled interactions between epithelial cells of gastrointestinal mucosa and 
micelles, which in turn prolonged gastric residence time of paclitaxel. In vivo study showed 
an improvement of pharmacokinetic parameters after intravenous and oral administration of 
PTX-loaded stabilized Pluronic micelles. Both, the prolonged gastric residence and the high 
physical stability of micelles achieved by cross-linking of micelle core, have been considered 
prerequisite for the efficient oral paclitaxel absorption.  
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Table 1. Physico-chemical properties of non-loaded stabilized Pluronic micelles (PM), 
rhodamine-loaded (R-PM) and paclitaxel-loaded micelles (PTX-PM). Data expressed as the 
mean ± SD, n=3. 
 
 
Sample 
 
Size, nm 
 
PI 
 
Zeta-potential, mV 
 
 
PM 
 
177.2 ± 8 
 
 
0.252 
 
-12.4 ± 3 
 
R-PM 165.4 ± 16 
 
0.372 -17.2 ± 3 
 
PTX-PM 180.0 ± 5 0.235 -15.2 ± 2 
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Table2. Plasma pharmacokinetic parameters (mean ± SD) of polymeric micelles in C57BL/6J 
female mice following a single i.v. and oral administration. Dose PXL= 10 mg/kg. 
 
 
Sample Route AUC (µg h/mL) 
C max 
(ng) 
 
T 
max 
(h) 
T ½ Z 
(h-1) 
MRT 
(h) 
V 
 (mL) 
Cl 
(mL/h) F 
Taxol ® i.v. 90.2±24.5 60.5±6.4 0 2.27±0.5 1.39±0.4 5.8±0.6 2.7±0.3  
PTX-PM i.v. 110.0±29.1 68.1±3.8 0 2.2±0.1 5.1±2.4 6.3±0.6 1.3±0.8  
Taxol ® Oral ND ND ND ND ND ND ND ND 
PTX-PM Oral 99.2±17.3 19.2±3.6 0.5 0.1±0.0 12.7±1.6 12.3±1.5  1.1±0.3 0.9 
AUC area under the concentration-time curve from time 0 to 8; Cmax: peak concentration; 
Tmax: time to peak concentration; MRT: mean residence time; t1/2z: half-life of the terminal 
phase. F: oral bioavailability.  
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Figure 1. Chart diagrams representing the ratio between the size of the micelles observed after 
24h incubation in different media to initial size measured in distilled water. 
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Figure 2. Influence of the initial concentration of rhodamine (a) or paclitaxel (b) on the 
loading degree into micelles and encapsulation efficiency. Data expressed as the mean ± SD, 
n=3.  
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Figure 3. Distribution of the rhodamine in the gastrointestinal segments after oral 
administration of rhodamine-loaded stabilized Pluronic micelles (R-PM). St-stomach, 
intestinal parts: I1 – duodenum, I2 and I3 - jejunum, I4 representing ileum, C-caecum). 
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Figure 4. Remained rhodamine fractions in the gastrointestinal segments of rats 8 hours after 
oral administration of rhodamine-loaded stabilized micelles and control rhodamine solution.  
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Figure 5. Paclitaxel plasmatic levels after intravenous administration (single dose of 10mg/kg) 
of either stabilized paclitaxel-loaded micelles (PTX-PM) or Taxol®. Data expressed as mean 
± SD (n=5). 
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Figure 6. Paclitaxel plasmatic levels after oral administration (single dose of 10mg/kg) of 
either stabilized paclitaxel-loaded micelles (PTX-PM) or Taxol®. Data expressed as mean ± 
SD (n=5). 
 
 
